May 19, 2016
December 2015, Vol. 4, No. 6
Sample Size Calculation for Single-Arm Phase 2 Prostate Cancer Trials
Prostate cancer remains one of the major health issues for men worldwide and is the second leading cause of cancer-related death in males in the United States…
Related Articles
Interview with the Innovators - December 28, 2015
The Current Landscape in Melanoma Treatment
An Interview with Jeffrey Infante, MD, of Sarah Cannon Research InstituteThe COMBI-d and COMBI-v trials showed that treating BRAF V600 mutation–positive metastatic melanoma with the combination of dabrafenib plus trametinib resulted in a significant increase in overall survival and a 33% reduction in the risk of progression or death compared [ Read More ]
FDA Approvals, News & Updates - December 28, 2015
FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer
On November 23, 2015, the FDA approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, MD, Director of [ Read More ]